✦ LIBER ✦

Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion—The GFM experience

✍ Scribed by Fabien Le Bras; Marie Sebert; Charikleia Kelaidi; Thierry Lamy; François Dreyfus; Jacques Delaunay; Anne Banos; Michel Blanc; Norbert Vey; Aline Schmidt; Sorin Visanica; Virginie Eclache; Pascal Turlure; Odile Beyne-Rauzy; Agnès Guerci; Alain Delmer; Stéphane de Botton; Delphine Rea; Pierre Fenaux; Lionel Adès

Book ID: 113773465
Publisher: Elsevier Science
Year: 2011
Tongue: English
Weight: 197 KB
Volume: 35
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2011.05.034

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Treatment of myelodysplastic syndromes w

Treatment of myelodysplastic syndromes with 5q deletion before the lenalidomide era; the GFM experience with EPO and thalidomide

✍ C. Kelaidi; S. Park; S. Brechignac; L. Mannone; N. Vey; H. Dombret; L. Aljassem; 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 98 KB

Lenalidomide in the Myelodysplastic Synd

Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion

✍ List, Alan; Dewald, Gordon; Bennett, John; Giagounidis, Aristotle; Raza, Azra; F 📂 Article 📅 2006 🏛 Massachusetts Medical Society 🌐 English ⚖ 203 KB

Multivariate time-dependent comparison o

Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion

✍ Sánchez-García, Joaquín; del Cañizo, Consuelo; Lorenzo, Ignacio; Nomdedeu, Benet 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 368 KB

Lenalidomide in lower-risk myelodysplast

Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents

✍ David Sibon; Giovanna Cannas; Fiorenza Baracco; Thomas Prebet; Norbert Vey; Anne 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 140 KB

High level of full-length cereblon mRNA

High level of full-length cereblon mRNA in lower risk myelodysplastic syndrome with isolated 5q deletion is implicated in the efficacy of lenalidomide

✍ Jonasova, Anna; Bokorova, Radka; Polak, Jaroslav; Vostry, Martin; Kostecka, Arno 📂 Article 📅 2014 🏛 John Wiley and Sons 🌐 English ⚖ 254 KB

Changes in RPS14 expression levels durin

Changes in RPS14 expression levels during lenalidomide treatment in Low- and Intermediate-1-risk myelodysplastic syndromes with chromosome 5q deletion

✍ Esther N. Oliva; Maria Cuzzola; Francesco Nobile; Francesca Ronco; Maria Grazia 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB